The pharmacokinetics of a single rectal dose of paracetamol (40 mg·kg−1) in children with liver disease
Version of Record online: 14 MAR 2006
Volume 16, Issue 4, pages 417–423, April 2006
How to Cite
CORMACK, C.R.H., SUDAN, S., ADDISON, R., KEATING, J., SHERWOOD, R.A. and ASHLEY, E.M.C. (2006), The pharmacokinetics of a single rectal dose of paracetamol (40 mg·kg−1) in children with liver disease. Pediatric Anesthesia, 16: 417–423. doi: 10.1111/j.1460-9592.2005.01789.x
- Issue online: 14 MAR 2006
- Version of Record online: 14 MAR 2006
- Accepted 4 October 2005
- chronic liver disease
Background: The aim of our study was to measure the serum paracetamol concentrations achieved following a single rectal loading dose of 40 mg·kg−1 in children with chronic liver disease.
Methods: We recruited 17 children (3–15 years, 10.6–75 kg) undergoing minor surgical procedures under general anesthesia. Paracetamol was administered at the end of surgery and blood samples were taken for analysis at 2, 3, 4, 6 and 8 h postdose.
Results: The mean Cmax of 11.4 mg·l−1 [coefficient of variation (CV) 66%] was achieved at a Tmax of 2.7 h (CV 42%). The relative bioavailability (F) of the suppository formulation was not estimated, but clearance (Cl/F) estimates 0.73 l·kg−1·h−1 (CV 87%) and time–concentration profiles for these children were similar to the normal pediatric population.
Conclusions: There are currently no biologic markers available for monitoring possible hepatotoxicity in this cohort of patients with liver disease, but our data suggest that a single-dose suppository is a satisfactory analgesic alternative.